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Background: The purpose of this study was to investigate the impact of metabolic syndrome (MS) on outcome
of catheter ablation (CA) for treatment of frequent premature ventricular contraction beats (PVCs) originating from
right ventricular outflow tract (RVOT), left ventricular outflow tract (LVOT) or coronary cusps (CUSPs), in patients with
normal ventricular systolic function and absence of cardiac structural disease.
Methods: In this multicentre prospective study we evaluated 90 patients with frequent PVCs originating from RVOT
(n = 68), LVOT (n = 19) or CUSPs (n = 3), treated with CA. According to baseline diagnosis they were divided in
patients with MS (n = 24) or without MS (n = 66). The study endpoint was a composite of recurrence of acute or
delayed outflow tract ventricular arrhythmia: acute spontaneous or inducible outflow tract ventricular arrhythmia
recurrence or recurrence of outflow tract PVCs in holter monitoring at follow up.
Results: Patients with MS compared to patients without MS showed a higher acute post-procedural recurrence of
outflow tract PVCs (n = 8, 66.6%, vs. n = 6, 9.0%, p = 0.005). At a mean follow up of 35 (17-43) months survival free of
recurrence of outflow tract PVCs was lower in patients with baseline MS compared to patients without MS diagnosis
(log-rank test, p < 0.001). In cox regression analysis, only MS was independently associated with study endpoint
(HR = 9.655 , 95% CI 3.000-31.0.68 , p < 0.001).
Conclusions: MS is associated with a higher recurrence rate of outflow tract PVCs after CA in patients without
structural heart disease.Background
According to the Third report of the National Cholesterol
Education Program (NCEP) expert panel on detection,
evaluation, and treatment of high blood cholesterol in
adults (Adult Treatment Panel III) [1], metabolic syn-
drome (MS) is a clinical condition defined by evidence of
several risk factors including obesity, hypertension, dia-
betes, and dyslipidaemia and it is related to a pro inflam-
matory and pro thrombotic state [2]. MS identifies* Correspondence: raffaele.marfella@unina2.it
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unless otherwise stated.patients at increased risk for cardiovascular disease
(CVD), type 2 diabetes mellitus, and all-cause mortality
[3-5], and approximately one-fifth of the adult U.S. popu-
lation would be classified as having MS with an upward
trend in abdominal obesity and insulin resistance [6]. Pa-
tients with uncomplicated MS have a greater dispersion of
ventricular repolarization time and augmented maximal
and minimal QTc [7], with increased possibility of ven-
tricular re-entry circuits [8-10] and increased frequency of
premature ventricular contractions (PVCs) compared to
healthy controls [11,12]. Ventricular arrhythmias and
PVCs originating from right ventricular or left ventricular
outflow tract (RVOT, LVOT) and coronary cusps (CUSPs),his is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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branch block (LBBB) morphology and V3 or V4 precordial
transition on surface electrocardiogram (ECG) are often
benign and not related to structural heart disease [13].
These arrhythmias are caused by triggered activity due to
cyclic adenosine monophosphate (cAMP)- mediated
calcium-dependent delayed after depolarizations, and re-
lated to a arrhythmogenic cell focus firing and triggering
induction mechanisms like catecholamine infusion, and
are responsible to adenosine as well as verapamil adminis-
tration [14]. Recent data evidenced the role of oxidative
stress in initiating cardiovascular consequences in MS.
The enhanced oxidative stress exacerbates inflammation,
which in turn further exacerbates oxidative stress, generat-
ing a vicious cycle, leading to sympathetic over activity
and eventually ventricular arrhythmias [15]. Thus, sympa-
thetic over activity state related to MS may represent an
irritating and triggering mechanism on these outflow tract
PVCs. According to guidelines there is a class I indication
for ventricular arrhythmias catheter ablation (CA) in pa-
tients at low risk for sudden death, in absence of structural
heart disease [16] and authors have observed beneficial ef-
fects on left and right ventricular function in patients with
PVCs and preserved left ventricular ejection fraction [17].
There are no evidences about catheter ablation (CA) out-
comes in MS patients affected by idiopathic or benign
PVCs. In this context, our study hypothesis is to examine
the impact of MS on CA outcome of idiopathic PVCs in
patients with preserved ventricular systolic function and
absence of cardiac structural disease.
Methods
Patient population
In this multicentre prospective study we evaluated, from
September 2010 to December 2013, all consecutive pa-
tients (n = 90) who were treated by CA of idiopathic
focal PVCs, originating from the RVOT (n = 68), LVOT
(n = 19) or CUSPs (n = 3), at Federico II university of
Naples (Naples, Italy), S. Maria di Loreto Mare Hospital
(Naples, Italy), and S. Maria Terni Hospital (Terni, Italy).
Inclusion criteria were: 1) presence of RVOT, LVOT or
CUSPs origin PVCs, 2) all patients have discontinued
the anti-arrhythmic drugs (AADs) 4-5 half live before to
perform the ablation, 3) absence of any structural heart
disease, normal ventricular systolic function, 4) normal
thyroid function and electrolyte values, 5) normal renal
function, 6) absence of neoplastic disease. For every pa-
tient to rule out structural heart disease, a comprehen-
sive clinical evaluation was performed, which included
medical history, 12-lead electrocardiogram (ECG), and
two dimensional transthoracic echocardiography. If ex-
clusion of structural heart disease was deemed neces-
sary, exercise testing, coronary angiography, cardiac
multidetector computed tomography (CMCT), and/ornuclear imaging were performed. Prior to CA, 12-lead ECG
recording of the PVCs and 24-hour Holter registration
were acquired for all patients, and the evidence of more
than three consecutive monomorphic PVCs beats were
classified as ventricular tachycardia (VT). Baseline fasting
blood samples were obtained from all patients for the
measurement of blood glucose, lipid profile, and C Reactive
Protein (CRP) (Elecsys 2010, Roche Diagnostics). The CRP
cut off value was set at 0.9 mg/dl, with values below and
above this cut off considered normal and high, respectively.
Nitrotyrosine plasma concentration was assayed by
enzyme-linked immunosorbent assay. Nitrotyrosine was
determined because this modified amino acid is a product
of free-radical (O2–) interaction with nitric oxide (NO). The
interaction of O2– with NO leads to a rapid inactivation of
NO and to a production of the potent oxidant peroxyni-
trite. Detection of nitrotyrosine is strongly suggestive of in-
creased generation of peroxynitrite [18]. Patients were
diagnosed with MS if they had at least 3 of these risk fac-
tors, according to Adult Treatment Panel III MS definition
[1]: waist circumference >102 cm in men and 88 cm in
women, high-density lipoprotein <40 mg/dl in men and
<50 mg/dl in women and serum triglycerides >150 mg/dl,
blood pressure >130/85 mm Hg or on antihypertensive
medication, fasting blood glucose >100 mg/dl or on antidi-
abetic medication. According to authors [19] if body mass
index is over 30 kg/m2, central obesity can be assumed
and waist circumference does not need to be measured.
The study was approved by institutional review boards
and ethics committees at Federico II university of Naples
(Naples, Italy), S. Maria di Loreto Mare Hospital (Naples,
Italy), and S. Maria Terni Hospital (Terni, Italy). All pa-
tients provided written informed consent.
Ablation procedure
In discontinuation of AADs 4-5 half live before perform-
ing the electrophysiological study and catheter ablation,
and in conscious sedation by transfemoral right femoral
vein access a quadripolar diagnostic catheter 4 mm fixed
curve (Biosense Inc., Diamond Bar, CA; St. Jude Medical,
Inc., St. Paul, MN, USA ) has been placed first in right
ventricle apex and subsequently in RVOT for reference
and pacing manoeuvres. In the presence of clinical
PVCs, activation mapping was performed using a 4-mm
tip ablation catheter, placed by transfemoral right fem-
oral vein (RVOT) or artery (LVOT and CUSPs) and pace
mapping was performed in addition to activation map-
ping to identify the PVC focus during sinus rhythm. In
patients without spontaneous PVCs, programmed ven-
tricular stimulation was performed from the right ven-
tricular (RV) apex and RVOT at three drive cycle lengths
with up to three extra stimuli and incremental burst
pacing at a cycle length up to 250 ms, at baseline and
during isoproterenol infusion. All endocavitary signals
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cardiologist by a polygraph (Lab System Pro, Bard Elec-
trophysiology, Lowell, MA, USA). In all patients, a
three-dimensional non-fluoroscopic imaging and map-
ping system (CartoXP and Carto 3, Biosense Inc.,
Diamond Bar, CA; Ensite Navx, St. Jude Medical, Inc.,
St. Paul, MN, USA) was used for catheter localization
and activation mapping. Radiofrequency energy was de-
livered with a 4-mm-tip non irrigated catheter (Biosense
Inc., Diamond Bar, CA, or St. Jude Medical, Inc.,
St. Paul, MN, USA ) with a target temperature of 60°C
at a power of 35 W or with a 4-mm-tip irrigated ablation
catheter (Biosense Inc., Diamond Bar, CA or St. Jude
Medical, Inc., St. Paul, MN, USA) in temperature-
controlled mode with a target temperature of 45°C at a
power of 30 W. If the PVCs were abolished within 20 sec-
onds, the energy application was continued for 60 seconds,
while if PVCs were still present after 25-30 seconds, the en-
ergy application was terminated, and mapping was contin-
ued to find an optimal target site. After catheter ablation
programmed ventricular stimulation performed from the
right ventricular (RV) apex and RVOT at three drive cycle
lengths with up to three extra stimuli and incremental burst
pacing at a cycle length up to 250 ms, at baseline and dur-
ing isoproterenol infusion. On and off isoproterenol infu-
sion were utilized to confirm the effectiveness of CA in all
patients. Acute success was defined as the absence of out
flow tract PVCs with similar morphology during a 30 mi-
nutes observation period after CA, and in absence of clin-
ical PVCs during programmed ventricular stimulation.
End point
The end point was considered a composite of 1. acute
absence of spontaneous or inducible outflow tract PVCs
(OT-PVCs), with isoproterenol infusion or bursts
pacing from right ventricular apex and RVOT for 30 mi-
nutes following the last radiofrequency lesion, and 2.
delayed and late recurrence of OT-PVCs at a rate of ≤
300 beats per day documented by 24 h Holter monitor-
ing at scheduled follow up visits.
Follow up
All patients were followed in the outpatient department
within 2 weeks, and thereafter at monthly intervals, dur-
ing which physical examination and 12-lead ECG were
conducted. Routine 12-lead Holter monitoring was per-
formed at the 1st, 3rd, 6th and 12th month and echocar-
diography was performed at the 3rd and 6th month
floow-up. Whenever patients had symptoms of palpita-
tions, dizziness, or syncope during follow-up, they were
advised to contact their doctors immediately for evalu-
ation of vital signs, 12-lead ECG, and12-lead 24 hour
Holter monitoring. All AADs were discontinued after
successful ablation procedure.Statistical analysis
Statistical analyses were carried out with a package of
SPSS software version 20 (SPSS Inc., Chicago, IL, USA).
Kolmogorov-Smirnov test was used to check the Gaussian
distribution of continuous variables. Continuous variables
were presented as mean ± standard deviation if normally
distributed or as median (interquartile range), otherwise.
Categorical variables were presented as number and fre-
quencies. Patients were dichotomized according baseline
diagnoses of MS. The Student’s t-test or Mann-Whitney
test were used to compare continuous variables as appro-
priate. Additionally, χ2 test or Fisher’s exact test, were used
to compare categorical variables, as recommended. All
long term survival analyses were calculated from the date
of the procedure. The Log-rank test for time-to-event data
with respect to recurrence of study endpoint was used for
statistical comparison between patients with and patients
without MS. Univariate and multivariate Cox proportional
hazards models were performed to identify independent
associates of the endpoint. The estimated hazard ratios
and the 95% confidence intervals were computed. Only
univariate variables with p <0.05 were included in the
multivariate model. For multivariate modelling, BMI >
30 kg/m2, hypertension, dyslipidaemia and diabetes were
omitted due to collinearity with MS. A two-sided p <0.05
was considered statistically significant.
Results and discussion
The mean age of the population was 40 ± 16 years (male
53.3%). By definition, patients with MS had higher BMI,
and higher rates of dyslipidaemia, hypertension, and dia-
betes (Table 1). Creatinine, Nitrotyrosine and C Reactive
Protein (CRP) were also higher in the MS group (1.1
(1.0-1.2) mg/dl vs 1.0 (0.9-1.0) mg/dl, p = 0.004, 0.42 ±
0.03 μmol/L v/s 0.27 ± 0.02 μmol/L, p < 0.001 and 5.3
(3.2-7.2) mg/dl, vs. 2.7 (1.7-4.0) mg/dl, p < 0.001, respect-
ively). Values of oxidative stress marker (nitrotyrosine)
levels were higher in MS group (Table 1). Patients with MS
compared to patients without MS were more commonly
treated with angiotensin-converting enzyme inhibitors and
angiotensin receptor blockers (ACE/ARB blockers), beta-
blockers and lipid-lowering therapy (Table 1). Interestingly,
patients with MS as opposed to patients without MS had
higher baseline heart rate (HR) (72 ± 11 beats/min vs. 65 ±
10 beats/min, p = 0.015), higher PVCs burden at baseline
(7263 ± 1766 beats/day vs 7263 ± 1766 beats/day, p = 0.042)
and longer CA procedural time (163.9 ± 39.1 min vs. 141 ±
24 min, p = 0.002) (Table 2).
Study endpoint
There were 14 cases of acute PVCs recurrence (15,5%).
The rate of spontaneous or inducible PVCs with iso-
proterenol infusion and bursts pacing from right ven-
tricular apex and RVOT for 30 minutes following the
Table 1 Baseline population characteristics
Variable Total population Patients with MS Patients without MS p-value
(n = 90) (n = 24) (n = 66)
Age (years) 40 ± 16 53 ± 12 35 ± 15 <0.001
Male n(%) 48 (53.3%) 10 (41.6%) 38 (57.5%) 0.181
BMI (kg/m2) 27.7 ± 3.3 31.7 ± 1.2 26.3 ± 2.6 <0.001
Dyslipidemia n (%) 32 (35.6%) 22 (91.6%) 10 (15.1%) <0.001
Hypertension n (%) 41 (45.6%) 23 (95.8%) 18 (27.2%) <0.001
Diabetes n (%) 10 (11.1%) 10 (41.6%) 0 (0%) <0.001
Creatinine (mg/dl) 1.0 (0.9-1.2) 1.1(1.0-1.2) 1 (0.9-1.0) 0.004
Nitrotyrosine (μmol/L) 0.31 ± 0.07 0.42 ± 0.03 0.27 ± 0.02 <0.001
CRP (mg/dl) 3.7 (1.8-5.3) 5.3 (3.2-7.2) 2.7 (1.7-4.0) <0.001
PVCs origin site
RVOT n (%) 68 (75.6%) 20 (83.3%) 48 (72.7%) 0.791
LVOT n (%) 19 (21.1%) 3 (12.5%) 16 (24.2) 0.227
CUSPs n (%) 3 (3.3%) 1 (4.1%) 2 (3.0%) 0.610
Echocardiography
LVTDd (mm) 50.0 ± 5.5 50.1 ± 5.3 50.0 ± 5.5 0.933
LVTSd (mm) 28.7 ± 4.6 30.2 ± 4.3 28.1 ± 4.6 0.058
LVEF (%) 57 ± 5 57 ± 3 57 ± 5 0.982
Medication
ACEi/ARBs n (%) 33 (36.7%) 21 (87.5%) 12 (18.1%) <0.001
Beta blockers n (%) 16 (17.8%) 13 (54.1%) 3 (4.5%) <0.001
Lipid-lowering therapy n (%) 29 (32%) 19 (79.1%) 10 (15.1%) <0.001
Class I AADs n (%) 16 (17.8%) 11 (45.8%) 5 (7.5%) <0.001
Class III AADs n (%) 3 (3.3%) 2 (8.3%) 1 (1.5%) 0.172
Class IV AADs n (%) 3 (3.3%) 2 (8.3%) 1 (8.3%) 0.172
Follow-up months n (%) 39 (32-45) 35 (24-45) 40 (34-45) 0.356
Continuous variables are expressed as mean ± SD if normally distributed or as median (IQR: 25th percentile, 75th percentile) if not normally distributed, categorical
variables are expressed as number (percentage). AADs anti arrhythmic drugs; ACEi/ARBs blockers angiotensin-converting enzyme inhibitors and angiotensin receptor
blockers; CRP C-reactive protein; CUSPs aortic cusps; LVEF left ventricle ejection fraction; LVOT left ventricular outflow tract; LVTDd left ventricle end-diastolic diameter;
LVTSd left ventricle end-systolic diameter; PVCs premature ventricular contractions; RVOT right ventricular outflow tract.
Table 2 HR, PVCs morphology, PVCs burden and ablation procedure characteristics
Variable General population Group 1 (with MS) Group 2 (without MS) P Value
(n = 24) (n = 66)
HR baseline (bpm) 67 ± 10 72 ± 11 65 ± 10 0.015
PVC burden 7455 ± 2021 8226 ± 2 407 7263 ± 1766 0.042
QS wave in DI n (%) 23 (25.6%) 4 (16.6%) 19 (28.7%) 0.244
Precordial transition
before V4 n (%)
11 (12.2%) 2 (8.3%) 9 (13.6%) 0.721
Fluoroscopic time (min) 22.8 ± 10.2 22.7 ± 8.0 20.5 ± 9.1 0.299
RF time (min) 6.54 ± 3.4 7.2 ± 2.8 6.2 ± 3.5 0.206
Procedural time (min) 147.55 ± 30.8 163.9 ± 39.1 141 ± 24 0.002
Variables are expressed as mean ± SD or median (IQR: 25th percentile, 75th percentile) if not normally distributed.
AADs, antiarrhythmic drugs; HR, heart rate in beats for minute (bpm); PVC, premature ventricular beats; QS wave in DI derivation on surface ecg;
RF, radiofrequency catheter ablation.
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higher in patients with MS compared to patients without
MS (n = 8, 66.6%, vs. n = 6, 9.0%, p = 0.005). During a fol-
low up there were, 8 more patients (8,8%), evidenced of
PVCs at a rate of > 300 beats per day documented by
24 h Holter. In total, 22 (24.4%) patients reached the
study endpoint (14 patients had acute and 8 patients de-
layed PVCs). None of the patients died during follow-up.
The Kaplan–Meier curves show survival rates free of
the composite study endpoint for patients divided ac-
cording to baseline diagnosis of MS (Figure 1). The re-
currence of acute or delayed PVCs free survival at 12
and 24 months follow up in the MS group were 50% and
9% compared with 89% and 87% in the group of patients
without MS, respectively (log-rank p < 0.001) (Figure 1).
From the univariate Cox proportional hazards analysis,
MS (HR = 9.119, 95% CI =3.461-24.024, p < 0.001), CRP
(HR = 1.253 95% CI = 1.035-1.516, p = 0.021), and proced-
ural time (HR = 1.015, 95% CI = 1.004-1.027, p = 0.015)
were included in the multivariable model (Table 3). Fi-
nally, only MS was independently associated with the
study endpoint (HR = 9.119, 95% CI = 3.461-24.024, p <
0.001) (Table 3).
Complications
After CA 3 hematoma complications, 1 arteriovenous
fistula and 1 case of acute pericardial effusion occurred.
During the follow up in the catheter ablation failure
group, patients remained under AADs and 14 (58,3%) of
them experienced a drug related adverse effect: symp-
tomatic low blood pressure in flecainide treated patientsFigure 1 Recurrence-free survival in patients with PVCs.
Kaplan Meier curve showing survival free of study endpoint between
patients with or without metabolic syndrome (Log-rank test, p < 0.001).
MS =metabolic syndrome; PVCs = outflow tract premature ventricular
contractions; Pts = patients.(n = 5), obstructive acute lung disease, hypotension and
symptomatic bradycardia in beta blockers treated pa-
tients (n = 7), and recurrent headaches and hypotension
in propafenone group (n = 2).
In this study we have examined the impact of MS on
acute and long term follow up catheter ablation in a
population of PVCs patients without evidence of struc-
tural heart disease and normal heart function. Our main
observations were the following: 1. in the overall popula-
tion who had undergone CA for PVCs, MS was associ-
ated with significantly higher acute CA failure. 2. MS
was an independent prognostic factor of acute and de-
layed PVCs recurrence after CA.
MS has some direct or indirect influence on ventricu-
lar electrophysiology by different action pathways and al-
tering the ionic channels conduction properties. The
higher prevalence of obesity, dyslipidaemia, hypertension
and diabetes leads MS patients to an augmented oxida-
tive stress and arrhythmogenesis, with abnormalities in
sympatho-vagal balance, QT interval and QT dispersion
and a fibrotic and adipotic Cardiac Conduction System
involvement [7-10].
The obesity, a common risk factor associated with MS
[2], can lead to high rates of sudden cardiac death (SCD),
before the development of heart disease [20,21], and an in-
creased frequency of premature ventricular contractions
compared to healthy controls, unrelated to hypertension
or concentric ventricular hypertrophy [22,23].
Elevated plasma free fatty acid level has a stimulatory
effect on the sympathetic nervous system [24], with an
increased sympathetic and a decreased parasympathetic
tone in obese patients [25].
Adipocytokines from epicardial fat significantly de-
crease delayed rectifier outward currents prolonging ac-
tion potential duration and facilitating triggered activity
with early after depolarizations [9], increasing disper-
sions of action potential duration and leading to a higher
possibility of re-entry circuits [9-11], causing ventricular
tachycardia and sudden cardiac death [22]. In our study
there is an higher baseline heart rate and PVCs burden
in MS than in overall population which may be ex-
plained by an abnormal sympatho-vagal balance in MS
population, and by a Conduction System involvement
with conduction channels alterations and an augmented
susceptibility to arrhythmogenesis.
The augmented systemic oxidative stress is associated
with cardiac electrical and structural remodelling [26-28],
and reactive oxygen species may impair Na, K, Ca channels
and Na-Ca exchanger activity, leading to gap junction re-
modelling, decreasing the action potential amplitude and
duration, and increasing the incidence of cardiac arrhyth-
mias in animal models [15]. In fact, oxidative stress results
in decreased hERG protein levels, accelerated activation
and deactivation of hERG, increased in current amplitude
Table 3 Multivariate cox regression analysis for parameters associated with study endpoint
Variable Univariate analysis Multivariate analysis
HR (95% CI) p-value HR (95% CI) p-value
MS 9.119 (3.461-24.024) <0.001 9.655 (3.000-31.068) <0.001
Age (years) 1.023 (0.997-1.050) 0.083
*BMI ≥ 30 (kg/m²) 8.1 (3.0-21.454) <0.001
Hypertension 2.656 (1.068-6.604) 0.036
Dyslipidemia 3.447 (1.417-8.384) 0.006
Diabetes 2.785 (1.015-7.638) 0.047
Creatinine (mg/dl) 0.652 (0.162-2.616) 0.546
*Nitrotyrosine × 100 (μmol/L) 1.136 (1.074-1.202) <0.001 0.64 (0.12-3.52) 0.611
CRP (mg/dl) 1.253 (1.035-1.516) 0.021 0.940 (0.767- 1.151) 0.977
Heart rate baseline (bpm) 1.011 (0.973-1.051) 0.573
PVC burden (per 100 beats/24 hours increase) 1.017 (0.997-1.038) 0.096
BMI body mass index; CRP C reactive protein; HR Hazard Ratio; PVC premature ventricular contractions.
*MS, BMI and Nitrotyrosine levels were significantly associated with the study endpoint, P<0.001.
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to flow through these channels in the phase 3 of the action
potential, down regulation of Ito (transient outward potas-
sium current) responsible for the rapid repolarization
phase, and increased the channel opening probability of
Ik1 (inward rectifying channel) [27,28].
The alteration in cardiac oxidative stress, investigated by
an higher expression of serum biomarkers like nitrotyro-
sine and C reactive protein (CRP), leads to alterations in
ionic channels conductions properties favouring arrhyth-
mogenic activity in MS population.
At long term these irritative and pro inflammatory
stimuli may become pro fibrotic leading to structural fi-
brotic alterations of the sinoatrial node and throughout
the conduction system, the atrioventricular node, atrio-
ventricular bundle and left bundle branch [29]. Added to
these fibrotic alterations other structural abnormalities such
as localized wall bulging, wall thinning, fatty infiltration,
and fibrosis exist in the RVOT, not only in patients with
Arrhythmogenic Right Ventricle Cardiomyopathy (ARVC),
[30,31] but also in patients with RVOT tachycardia [32].
If these subclinical myocardial structural alterations
may be an important factor limiting the efficacy of CA
outcome in general population [33], in MS patients with
different morphology of PVCs on surface ECG (different
precordial transition and q wave in lead I) and PVCs ori-
gin focus have shown not different outcomes, observing
all PVCs population and separately RVOT, LVOT and
CUSPs PVCs.
This may be explained because, in MS patients, the
presence of a constellation of risk factors can alter and
affect the prognosis also in evidence of a good ablation
target, and in our study the only independent predictor
of short and long term follow up catheter ablation fail-
ure is MS.In the two groups there is not a difference regarding
the fluoroscopic time and the ablation time (RF time),
while there is a significant difference related to total pro-
cedural time. We can explain these observations than to
the modern technologies utilized, because first in all pa-
tients we have utilized as described before two different 3D
non fluoroscopic mapping system (CartoXP and Carto 3,
Biosense Inc., Diamond Bar, CA; Ensite Navx, St. Jude
Medical, Inc., St. Paul, MN, USA), that help to record and
target more accurately tachycardia origin for ablation than
with fluoroscopy alone, and allow catheter positioning
without the use of fluoroscopy, reducing fluoroscopy time
and radiation dose [34-36], and secondary also for catheter
ablation we can consider to have utilized a standardized
protocol, using in more time same energy source (radiofre-
quency) with same target energy (watt), temperature and
pulse duration (maximum 60” for every ablation point).
On other hand the higher total procedural time observed
in MS may be due to technical difficulties related to mul-
tiple risk factors present in MS, than can influence the in-
traoperative management of MS patients prolonging the
total procedural time.
The multifactorial risk factors in MS altering oxido/re-
dux balance by a proinflammatory status, lead to an ab-
normal sympathetic tone and complex alterations in
electrophysiological properties from baseline in affected
patients.
All these molecular processes connected with MS rep-
resent a pro-inflammatory permanent condition trigger-
ing the arrhythmogenic cells firing in patients with
PVCs not related to cardiac structural disease and with-
out cardiac dysfunction, and leading to an higher ten-
dency and propensity to arrhythmogenicity.
In a recent study [37] authors have shown a worse
catheter ablation outcome in MS patients affected by
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proinflammatory status can affect ablation outcome.
Until now at our knowledge there are not studies fo-
cused on idiopathic PVCs catheter ablation outcome in
MS overall general population.
In our study we try to show the impact of MS on pa-
tients affected by idiopathic PVCs undergoing catheter
ablation therapy, without structural heart diseases and
altered cardiac function.
The investigated proinflammatory status and altered
sympathetic-vagal tone in MS population may identify at
baseline patients with less possibility to respond to CA,
also in absence of cardiac structural alterations and car-
diac dysfunctions and so apparently not different in this
from overall population if selected for CA of benign and
idiopathic PVCs.
These subclinical alterations are not simple to detect
with modern technologies, but in current clinical prac-
tice we could at last identify and treat step by step all
these risk factors implicated in MS, targeting in this way
a better control of a complex clinical condition like MS,
before to select MS patients candidates to idiopathic
PVCs catheter ablation.
In our opinion next clinical question may be to evaluate
in a future prospective randomized trial if a more effective
and aggressive control of all these risk factors associated
with MS may lead to a better ablation outcome.
This treatment before a catheter ablative approach in MS
may be more beneficial and influence short term and long
term follow up outcome of idiopathic or benign PVCs .
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Study limitations
Several limitations may have influenced our results.
First, although periodic 12-lead ECG and 24 hour Holter
were performed during the follow-up period, episodes of
asymptomatic PVCs or more serious arrhythmias might
have been missed in some patients. Second, the study
sample size and follow-up duration may have been insuf-
ficient to fully characterize the incidence of lethal ar-
rhythmias among study groups. Third, patients were not
followed for any status change in their MS component,
that may affect and influence long term ablation out-
come. Fourth, we did not obtain waist circumference
measurement data, which would have illustrated the ab-
dominal obesity status of the patients, which is consid-
ered by some as better tool to assess obesity.
Last, number of subjects and ages in the study and
control are not similar.Conclusions
The current study demonstrated that after PVCs catheter
ablation in structurally and functionally normal ventricles,
the patients with MS had significantly higher acute and
delayed recurrence rate of PVCs at follow up. Moreover,
MS was an independent predictor of arrhythmia recur-
rence during the follow-up. MS and its proinflammatory
status may represent a chronic irritative mechanism in
these patients, leading to subclinical alterations that can
affect catheter ablation outcomes, with an higher recur-
rence rate in PVCs mediated via inflammation.
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